prednisone has been researched along with Porokeratosis in 5 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Porokeratosis: A heritable disorder of faulty keratinization characterized by the proliferation of abnormal clones of KERATINOCYTES and lesions showing varying atrophic patches surrounded by an elevated, keratotic border. These keratotic lesions can progress to overt cutaneous neoplasm. Several clinical variants are recognized, including porokeratosis of Mibelli, linear porokeratosis, disseminated superficial actinic porokeratosis, palmoplantar porokeratosis, and punctate porokeratosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Whereas cutaneous sarcoidosis is present in up to one-third of cases and may present with a wide variety of lesions, our presentation is uncommon." | 1.42 | Cutaneous sarcoidosis simulating porokeratosis of Mibelli. ( Benchikhi, H; Chiheb, S; Elfatoiki, FZ; Jabri, L; Soussi, W, 2015) |
| "We report a case of disseminated superficial actinic porokeratosis (DSAP) with neutrophilic pustules within cornoid lamellae on histopathologic examination, corresponding to pustules along the elevated rim clinically as well." | 1.35 | Pustular porokeratosis. ( Miller, DD; Ruben, BS, 2009) |
| "Disseminated superficial actinic porokeratosis is the clinical variant of porokeratosis that most frequently develops in immunosuppressive states." | 1.33 | [Porokeratosis in a patient with dermatomyositis]. ( Cacharrón, JM; de las Heras, C; Durana, C; Ginarte, M; Labandeira, J; Monteagudo-Sánchez, B, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bednarek, R | 1 |
| Ezra, N | 1 |
| Toubin, Y | 1 |
| Linos, K | 1 |
| Mousdicas, N | 1 |
| Elfatoiki, FZ | 1 |
| Soussi, W | 1 |
| Chiheb, S | 1 |
| Jabri, L | 1 |
| Benchikhi, H | 1 |
| Miller, DD | 1 |
| Ruben, BS | 1 |
| Monteagudo-Sánchez, B | 1 |
| Ginarte, M | 1 |
| Durana, C | 1 |
| Labandeira, J | 1 |
| de las Heras, C | 1 |
| Cacharrón, JM | 1 |
| Fields, LL | 1 |
| White, CR | 1 |
| Maziarz, RT | 1 |
5 other studies available for prednisone and Porokeratosis
| Article | Year |
|---|---|
Eruptive disseminated porokeratosis associated with corticosteroid-induced immunosuppression.
Topics: Adrenal Cortex Hormones; Adult; Female; Humans; Immunosuppression Therapy; Immunosuppressive Agents; | 2015 |
Cutaneous sarcoidosis simulating porokeratosis of Mibelli.
Topics: Anti-Inflammatory Agents; Biopsy; Humans; Hydroxychloroquine; Male; Middle Aged; Porokeratosis; Pred | 2015 |
Pustular porokeratosis.
Topics: Antimetabolites, Antineoplastic; Azathioprine; Colitis, Ulcerative; Diabetes Mellitus, Type 2; Human | 2009 |
[Porokeratosis in a patient with dermatomyositis].
Topics: Aged; Dermatomyositis; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Methotrexat | 2006 |
Rapid development of disseminated superficial porokeratosis after transplant induction therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease | 1995 |